European regulators have agreed to review Clovis’ application to expand the use of its PARP inhibitor Rubraca in the region.
The company is seeking permission to market Rubraca (rucaparib) for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum based chemotherapy.
Read more: http://www.pharmatimes.com/news/clovis_parp_inhibitor_rubraca_under_eu_review_in_maintenance_setting_1243566